


# To boldly flow with Qdot® nanocrystals

## Now available: Qdot® nanocrystal–conjugated primary antibodies

Researchers today are trying to maximize information from their flow cytometry experiments by looking at more parameters in one sample. Qdot® nanocrystals provide a powerful way to increase your fluor selection from your available excitation sources. Qdot® nanocrystal conjugates will allow you to add 1–6 colors to your data acquisition from a violet laser and, in addition, provide the advantages of brightness and photostability.

The fluorescence properties of Qdot® nanocrystals are different from those of typical dye molecules. Typical fluorescent dyes have excitation and emission spectra with relatively small Stokes shifts, which means that the optimal excitation wavelength is close to the emission peak. Qdot® nanocrystals have broad absorbance spectra and are optimally excited by a UV or violet (405–407 nm) laser, although usable excitation can also be obtained with other sources such as the 488 nm laser. Their emission peaks are narrow and symmetrical, and do not change with excitation (Figure 1). Because of their spectral properties, Qdot® nanocrystals are brighter than most common fluors.


Qdot® nanocrystal conjugates may be used in the same way as conventional conjugates. Because staining conditions may vary, reagents should be titrated with samples to obtain optimal staining concentrations. Figure 2 shows typical profiles of human peripheral blood leukocytes (PBLs) stained with Qdot® nanocrystal conjugates specific for CD3, CD4, CD8, and CD14 antigens. The two-color combination was analyzed with <4% compensation between channels. In addition, Qdot® nanocrystals are compatible with common lysing, fixation, and permeabilization reagents, such as Cal-Lyse™ and FIX & PERM®.



**Figure 1—Recommended filter configuration and emission profiles for selected Qdot® nanocrystals.** Filter diagrams and emission curves were viewed with the Fluorescence Spectra Viewer (probes.invitrogen.com/resources/spectraviewer/).



## Primary antibody conjugates now available

As the exclusive provider of Qdot® nanocrystal technology for life science research, Invitrogen offers a full range of tools, from new primary antibody conjugates to secondary detection reagents, to maximize the use of your flow cytometer by combining Qdot® nanocrystal technology with existing organic fluorophores. For more information on using this new technology in flow cytometry, including detailed protocols and resources, visit [www.invitrogen.com/qdotforflow](http://www.invitrogen.com/qdotforflow).



**Figure 2—Staining profiles for Qdot® nanocrystal–conjugated antibodies.** Human peripheral blood leukocytes were stained with the specified Qdot® conjugates. Samples were analyzed using a BD™ LSR II flow cytometer with 405 nm excitation and the specified emission filters.

**NOW AVAILABLE!**



**OFFERING MORE THAN  
11,000  
QUALITY PRODUCTS  
for Cell Biology Research!**

**Request a catalog online:**  
[www.RnDSystems.com/go/Catalog](http://www.RnDSystems.com/go/Catalog)

Cancer Endocrinology Immunology Proteases Neuroscience  
Development Stem Cells Signal Transduction Glycobiology

Tools for Cell Biology Research™




Selection expanding weekly—visit [www.RnDSystems.com](http://www.RnDSystems.com) to sign up for weekly new product updates.

USA & Canada **R&D Systems, Inc.** Tel: (800) 343-7475 [info@RnDSystems.com](mailto:info@RnDSystems.com)  
Europe **R&D Systems Europe, Ltd.** Tel: +44 (0)1235 529449 [info@RnDSystems.co.uk](mailto:info@RnDSystems.co.uk)  
China **R&D Systems China Co., Ltd.** Tel: (21) 52380373 [info@RnDSystemsChina.com.cn](mailto:info@RnDSystemsChina.com.cn)

For research use only. Not for use in diagnostic procedures.

**R&D**  
SYSTEMS®

# NEW! Poietics® Human Natural Killer Cells



## Attacking immune cell research with primary human cells

Lonza now offers Human Natural Killer Cells for your immune cell research. Isolated from normal peripheral blood of screened, healthy donors, Poietics® Human Natural Killer Cells are:

- Highly homogeneous population of NK cells (≥90% pure) for more consistent results
- Positively or negatively selected for the CD56 antigen for greater flexibility in experimental design
- Cryopreserved for convenience at ≥5 million viable cells per amp
- Multiple immune cell types from same donor available, providing experimental flexibility
- Choose from large selection of donors to fit your experimental needs

For more information about NK cells and other Poietics® Immune Cells, please visit [www.lonzabioscience.com/immunecells](http://www.lonzabioscience.com/immunecells)



# **HEMOPHILIA ASSOCIATION OF NEW YORK**

## **REQUESTING PROPOSALS FOR RESEARCH GRANTS**

**To study novel methods of immune tolerance  
for hemophilia A patients with high titer inhibitors.**

Proposals should involve laboratory scientist/clinician collaboration and may be multi-institutional. They should be designed with the goal of a translational clinical trial being feasible at the end of the two-year funding period. If at that time the project is ready for clinical trial, further funding would be available to support that trial.

**ELIGIBILITY:** Applicants must hold an M.D., Ph.D. or equivalent degree and should be working for a domestic or foreign non profit institution or organization. Applicants need not be U.S. citizens and there are no restrictions on applicant age, race, gender or creed.

**AWARDS:** One or more awards of **up to** \$400,000 each over a two-year grant term are available initially. Institutional costs cannot exceed 10% each year's budget. The funding period for selected projects shall be July 1, 2008 through June 30, 2010.

**DEADLINE:** A Letter of Intent with a description of the proposed research plan, proposed methods and preliminary data should be submitted by **February 21, 2008** with the CVs and bibliographies of the investigators. The letter of intent must not exceed 2 single-spaced pages (in 12 pt. Times New Roman font).

After initial review, a number of applicants will be invited to submit full applications. Review of the full applications will be completed by June 18, 2008.

**SUBMISSION:** Medical & Scientific Committee  
Hemophilia Association of New York  
104 East 40<sup>th</sup> Street, Suite 506  
New York, NY 10016

The Hemophilia Association of New York is an independent voluntary health organization.  
Telephone: 212-682-5510 / Fax: 212-983-1114 / Email: [hany@bestweb.net](mailto:hany@bestweb.net)



The objective of PhARF is to encourage progress in allergy research through the recognition of an outstanding non-established investigator by means of an

## INTERNATIONAL AWARD of USD 50 000

This Award, characterized as a personal prize, is offered annually to a scientist, **less than 40 years of age**, who has made outstanding contributions to the field of allergy through creative and independent research efforts. The scientific achievements of the candidate should have contributed to a better understanding of allergic inflammation, as well as to improved diagnostic procedures and to improved treatment, resulting in optimal patient management.

### Subject for 2008 – “New Insights into the Mechanisms and Management of Allergic Disease”

Selection of the Award recipient will be made by an International Scientific Committee, made up of internationally recognized senior scientists, today chaired by Prof Paul O’Byrne, Firestone Institute for Respiratory Health, St. Joseph’s Healthcare and McMaster University, Hamilton, Ontario, Canada. The judgement of the International Scientific Committee will be based on the submission of an unpublished review article, describing the research achievements and research goals of the candidate. The contribution of the recipient of the International Award and Honorable Mention will be published.

For further information and to obtain **application forms**, please, visit PhARF at [www.phadia.com](http://www.phadia.com) or contact the: *PhARF Office*, attn: Marie Lantz, Phadia AB, P.O. Box 6460, F35-4, SE-751 37 Uppsala, Sweden – or e-mail: [marie.lantz@phadia.com](mailto:marie.lantz@phadia.com)

**The application must be received no later than April 4, 2008**

# IMMUNOLOGY



THE JOURNAL OF

## SPEND MORE TIME ON SCIENCE AND LESS TIME ONLINE

You have better things to do than spend hours submitting and tracking manuscripts.

*The JI's* new online manuscript submission and peer-review system is designed to make manuscript submission seamless for authors and peer review simple for reviewers.

### SUBMIT IN A SNAP!

Try our easy 4-step submission process.

Fast  
Efficient  
Easy to use

<http://ji.msubmit.net>



**"Sometimes you fall through a little trap door  
to a more exciting path."**

*Frederic Preffer, PhD* Director, Pathology Flow Cytometry Laboratories

Read more about what inspires  
Dr. Preffer's research:

[bdbiosciences.com/preffer](http://bdbiosciences.com/preffer)



Helping all people  
live healthy lives

BD supports researchers as they pursue  
promising pathways—offering a  
comprehensive flow cytometry portfolio  
including instrumentation, reagents,  
and collaborative services.

BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2008 BD  
23-9652-00

**BD Biosciences**  
2350 Qume Drive  
San Jose, CA 95131  
[bdbiosciences.com](http://bdbiosciences.com)